cyrilzakka/clinical-trials huggingface dataset:
Identification of Sports Talents in Boxers

This study aims to identify sporting talents by profiling a group of young boxers residing in the State of Mexico using unsupervised machine learning methods. This study is supported by Asociación de Boxeo del Estado de México AC (ABEM) and powered by DBSS.

This cross-sectional study aims to identify sporting talents by profiling a group of young boxers residing in the State of Mexico. The primary outcomes encompass anthropometric, physical, and psychological variables associated with sports performance. In detail, a morphological and body composition analysis will be conducted using anthropometric data. Boxing performance will be assessed by measuring the average acceleration of straight punches over 6 seconds, impact force in the straight boxing punch using a load cell, reactive force index in a counter-movement jump on a force platform, maximum isometric strength in the mid-thigh isometric pull on a force platform, load-velocity profile in the squat exercise using a linear encoder, and cardiorespiratory fitness measured with digital spirometry. Psychometric variables will include well-being level calculated with PERMA+4, attention capacity, perceptual acuity, concentration using the Toulouse test, and coping mechanisms assessed through the coping modes scale.

Eligibility Criteria:
Inclusion Criteria: Amateur boxers from the State of Mexico with no declared health issues -

Exclusion Criteria: Amateur boxers from the State of Mexico with any declared health issues

-
Assessing Pain as a Mediator of Behavior Change in Post-coronary Angioplasty Patients

The focus of this secondary data analysis is to determine whether pain due to a combination of both cardiac and non cardiac sources operates as a mediator of behavior change, an area that has not been previously evaluated.

This is a secondary data analysis of an existing dataset generated from The Healthy Behavior Trial, an NHLBI-funded randomized controlled trial that enrolled 660 post-coronary angioplasty patients between October 1999 and March 2001. This study employed a behavioral intervention to motivate PCI patients to adopt health behaviors in order to reduce major cardiac and neurologic morbidity and mortality. Patients in the experimental arm were told their estimated biologic age (calculated from the health risk assessment) and risk factors were presented in terms of "biologic age reduction" that could be achieved if a change was made in each health behavior area. Those in the control arm were provided with risk factors (also obtained from the health risk assessment) and told that changing each health behavior could "increase your lifespan."

Specific Aims:

Utilizing 12 month longitudinal data for patients with cardiovascular disease who have undergone coronary angioplasty we will:

Specific aim 1: Determine if pain is a mediator of health behavior change over 12 months.

Specific aim 2: Assess behavior change patterns over 12 months, stratifying for degree of pain, depression and/or stress.

Specific aim 3: Evaluate the effect of pain on quality of life (physical, social, role-physical, role-emotional, vitality, mental health, bodily pain and general health domains), combined major cardiac and neurologic morbidity/mortality and hospitalizations over 12 months.

Eligibility Criteria:
Inclusion Criteria:

* all patients in the database who had participated in the Healthy Behavior Trial. The Healthy Behavior Trial was a randomized controlled trial of a psychoeducational intervention designed to motivate multi-behavior change (changing 2 or more cardiovascular risk factors) in post-coronary angioplasty patients over the course of 24 months.

Exclusion Criteria:

* Non-participants in the Healthy Behavior Trial
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy

This study is designed to learn more about overall tau burden in the brain of patients with Progressive Supranuclear Palsy (PSP).


Eligibility Criteria:
Inclusion Criteria:

* Must be over 35 years of age and present with gradual progression of PSP-related symtoms
* Must have an informant or study partner that can provide independent information of functioning.
* Must meet criteria for possible or probable Progressive Supranuclear Palsy. To fulfill criteria for possible PSP, subjects must have a gradually progressive disorder with either vertical (upward or downward) supranuclear palsy or both slowing of vertical saccades and prominent postural instability with falls in the first year of disease onset. To fulfill criteria for probable PSP, subjects must have vertical (upward or downward gaze) supranuclear palsy and prominent postural instability with falls in the first year of disease onset.

Exclusion Criteria:

* Subjects will be excluded if they meet criteria for another neurodegenerative disease (including corticobasal syndrome, frontotemporal dementia, primary progressive aphasia, Alzheimer's disease, multiple system atrophy and Parkinson's disease) or do not have the symptoms necessary to fulfill inclusion criteria for possible PSP.
* Subjects with concurrent illnesses that could account for their symptoms, such as traumatic brain injury, encephalitis, strokes or developmental syndromes will be excluded.
* Women that are pregnant or post-partum and breast-feeding will be excluded.
* Subjects will be excluded from the study if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, and Down's syndrome.
* Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma, intracranial neoplasm or large cortical infarcts), or if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g. chemotherapy).
* Subjects will also be excluded if they do not have an informant, or do not consent to research.
Safety Study of Anti-Influenza Virus Monoclonal Antibody to Treat Influenza

The purpose of this study is to compare the safety profile in healthy volunteers of a single intravenous administration of TCN-032 as compared with placebo.

Influenza is a highly communicable acute respiratory disease that is considered to be one of the major infectious disease threats to the human population. Annual vaccination is generally effective only against those strains included in the vaccine. Because of the frequent emergence of divergent variants and the periodic emergence of strains with novel hemagglutinin and/or neuraminidase surface proteins that can result in global pandemics, the availability of potent antiviral agents for the prevention and/or treatment of influenza remains an urgent clinical and public health priority.

Eligibility Criteria:
Inclusion Criteria:

* Healthy volunteers
* Normal lab tests

Exclusion Criteria:

* Prior treatment with a monoclonal antibody
Allergy, Asthma, and Atopic Eczema in Finland

The summary is available at --\> https://www.finnatopy.fi/summary

Aims and objectives ---\> https://www.finnatopy.fi/aims-and-objectives Methods ---\> https://www.finnatopy.fi/methods

Eligibility Criteria:
Inclusion/Exclusion Criteria ---\> https://www.finnatopy.fi/methods
Effectiveness of Triple Therapy With Palonosetron for PON Prophylaxis

Postoperative nausea and vomiting (PONV) is a displeasing experience that distresses surgical patients during the first 24 hours after a surgical procedure. The incidence of postoperative nausea occurs in about 50%, the incidence of postoperative vomiting is about 30%, and in high-risk patients, the PONV rate could be as high as 80%. Therefore, the study design of this single arm, non-randomized, pilot study assessed the efficacy and safety profile of a triple therapy combination with palonosetron, dexamethasone and promethazine to prevent PONV in patients undergoing craniotomies under general anesthesia.

At induction of anesthesia, a triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg IV and promethazine 25 mg IV was given as PONV prophylaxis. After surgery, subjects were transferred to the surgical intensive care unit (SICU) or post anesthesia care unit as clinically indicated. Ondansetron 4 mg IV was administered as primary rescue medication to subjects with PONV symptoms. PONV was assessed and collected every 24 hours for 5 days via direct interview and/or medical charts review.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients, 18 to 85 years of age, of any race or gender. With an American Society of Anesthesiologist (ASA) physical status of I to III who are scheduled to undergo neurological surgery requiring opening of the cranium and Dura matter under general anesthesia, at Ohio State University Medical Center and who consent in writing to participating in this study.
* Post operative hospitalization expected to last at least 72 hours.
* Subjects whose surgery is expected to require at least 1 hours of general anesthesia
* Subjects who have a negative serum or urine pregnancy test within 1 day of surgery or who have been surgically sterilized or are postmenopausal.

Exclusion Criteria:

* Subjects who are prisoners, pregnant, mentally ill, under the age of 18 or over the age of 85, ASA classification of V, alcohol or drug abusers.
* Subjects with known hypersensitivity to any 5-HT3 antagonist, to any agent that is part of the anesthesia regimen, or to other medications to be administered under this protocol.
* Subjects who are breastfeeding.
* Subjects who have had retching/vomiting or moderate to severe nausea in the 24 hours prior to anesthesia or suffer chronic nausea and/or vomiting
* Subjects who have been treated with any drug or other treatment with anti-emetic efficacy within the last 24 hours prior to the start of treatment.
* Subjects who have participated in a clinical trial of an investigational drug within 30 days prior to surgery.
* Subjects who are participating in any other clinical study
A Study of SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC Participants

This single-arm, open-label, local multicenter study will evaluate the safety and tolerability of trastuzumab administered subcutaneously (SC) by a single-use injection device (SID) in participants with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC), following surgery and chemotherapy (neo-adjuvant or adjuvant).


Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast
* HER2-positive disease
* Eastern Cooperative Oncology Group (ECOG) performance status 0-1
* Hormonal therapy will be allowed as per institutional guidelines
* Prior use of anti-HER2 therapy will be allowed
* Left ventricular ejection fraction (LVEF) greater than or equal to (\>/=) 50 percent (%)
* No evidence of residual, locally recurrent or metastatic disease after completion of surgery and chemotherapy, or during concurrent chemotherapy (neo-adjuvant or adjuvant)
* Use of concurrent radiotherapy will be permitted
* Completion of surgery and chemotherapy (if applicable)

Exclusion Criteria:

* History of other malignancy, except for participants with curatively treated carcinoma in situ of the cervix or basal cell carcinoma and participants with other curatively treated malignancies who have been disease-free for the last 5 years
* Participants with severe dyspnea at rest or requiring supplementary oxygen therapy
* Participants with other concurrent serious diseases that might interfere with planned treatment, including severe pulmonary conditions/illness
* Serious cardiac illness or medical conditions that would preclude the use of trastuzumab, specifically: history of documented congestive heart failure, high-risk uncontrolled arrhythmias, angina pectoris requiring medication, clinically significant valvular disease, evidence of transmural infarction on electrocardiogram (ECG), poorly controlled hypertension
* Pregnant or lactating women
* Women of childbearing potential and male participants with female partners of childbearing potential who are unable or unwilling to use adequate contraceptive methods during study treatment
* Concurrent enrollment in another clinical trial using an investigational anti-cancer treatment, including hormonal therapy, biphosphonate therapy and immunotherapy, within 28 days prior to the first dose of study treatment
* Known hypersensitivity to trastuzumab, murine proteins, to any excipients of Herceptin, including hyaluronidase, or the adhesive of the SC device, or a history of severe allergic or immunological reactions, e.g. difficult to control asthma
* Inadequate hepatic or renal function
Effects of Iron on Exercise Capacity During Hypoxia

During alveolar hypoxia, for example at high altitude or in patients with respiratory disease, there is evidence to suggest that hypoxia-induced pulmonary hypertension might limit exercise performance. Intravenous iron supplementation has recently been shown to reverse pulmonary hypertension in healthy humans at high altitude, and to prevent pulmonary hypertension in volunteers exposed to hypoxia at sea level. The investigators hypothesized that intravenous iron supplementation would enhance exercise capacity during alveolar hypoxia.


Eligibility Criteria:
Inclusion Criteria:

* Age between 18 and 60 years
* Sea level natives with no recent exposure to high altitude
* Baseline iron indices within the normal range
* Detectable tricuspid regurgitation on echocardiography

Exclusion Criteria:

* Significant cardiorespiratory disease
* Known susceptibility to high altitude-related illness
* Taking medications or iron supplementation
* Pregnancy
A Trial for Evaluation of Clinical Efficacy and Safety of Healing Stone Navel Belt in Patients With Primary Dysmenorrhea

The purpose of this study is to determine whether Healing stone navel belt is safe and effective in the treatment of Primary Dysmenorrhea.


Eligibility Criteria:
Inclusion Criteria:

* Age : female adults aged 15\~45 years
* Subjects should diagnosed as primary dysmenorrhea, should have a primary dysmenorrhea at least a 1-day during menstrual.
* Subjects should have 21\~42 days menstrual cycle.
* menstrual pain : primary dysmenorrhea at least a 1-day during menstruation is over 5 VAS(Visual Analogue Scale) without drug.
* Subjects must have no Serious internal medicine.
* Subjects must provide signed informed consent prior to participation in any study-related procedures

Exclusion Criteria:

* Subject that oral contraceptive taken within 3 months
* Pregnancy or lactation.
* Subject have contraceptive that secrete hormone.
* Secondary dysmenorrhea
* pelvis inflammatory disease patient
* Other diseases or characteristics judged by the investigator to be incompatible with the assessments needed in this study or with reliable instillation of the study.
The Effect of Intraurethral Lidocaine Gel on Pain Perception During Flexible Cystoscopy

Flexible cystoscopy is routinely performed by urologists. Many patients have concerns to undergo this procedure and expect it to be unpleasant or even painful. Thus, reduction of pain and discomfort during cystoscopy is of great interest, but there is not sufficient evidence regarding the most appropriate conduct of cystoscopy.

In this study the impact of lidocaine gel, patient counseling and monitoring regarding pain perception during flexible cystoscopy are investigated.


Eligibility Criteria:
Inclusion Criteria:

* Men 18 - 80 years
* Given indication for flexible cystoscopy
* Written informed consent

Exclusion Criteria:

* Allergy to amid anesthetics
* Urinary tract infection
* Use of analgesics in the previous 24 hours and chronic intake of analgesics
* Dementia
* Presence of a sensory disorder such as or spinal cord injury
* Indwelling catheter carrier
The Role of Emotional Stress in Patients With Stress-induced Cardiomyopathy

The event-related potentials may be different in patients with Takotsubo cardiomyopathy than in patients without Takotsubo.

In patients with Takotsubo diagnosed by coronary angiography, the event-related potentials are investigated and compared with a control group, which consists of subjects without Takotsubo.

Eligibility Criteria:
Inclusion Criteria:

* Age \>18 years
* Written informed consent
* Takotsubo cardiomyopathy for group 1. ACS for group 3.

Exclusion Criteria:

* Psychiatric diseases
* Impaired versus, non compliant patients, heart disease for group 2.
* Takotsubo-like syndrome.
Virtual Reality Experiences on Acute Pain and Distress

The aim of this study is to evaluate the efficacy of virtual reality experiences on acute pain and distress caused by fluoroscopic pain intervention in chronic pain patient.

The investigators perform lots of interventions for patients. But unfortunately, patients cannot help being exposed to the acute pain and fear during the interventions. "Virtual Reality(VR)" is a state-of-art advanced technology, which is now being extended to various medical fields such as pain management, dental treatment, body rehabilitation and cancer pain. There is no study that have conjugated the virtual reality experience for patients' acute pain and anxiety which occurs during the pain interventions. So the investigators like to evaluate the effects of virtual reality experience on acute pain and anxiety precipitated by the pain interventions.

Eligibility Criteria:
Inclusion Criteria:

If all of the following conditions are met :

* Patient who has chronic pain lasting more than 3 months and whose pain doctor determined that he or she needs following fluoroscopic pain intervention : Lumbar sympathetic ganglion block (LSGB), Fluoroscopic-guided pulsed radiofrequency ablation (pRF), Fluoroscopic-guided radiofrequency thermocoagulation (hRF)
* Adults who are at least 20 years of age
* Patients whose American Society of Anesthesiologists(ASA) physical status is classified as 1 or 2.
* A person who voluntarily agrees to participate in this clinical trial and has agreed in informed consent.

Exclusion Criteria:

If the subject falls under any of the following conditions :

* Patients who cannot have virtual reality experience due to hearing or visual impairment
* If the patient has difficulty communicating due to lack of cognitive ability
* Patients that examiners deemed unsuitable for this trial
Reliability of 6-Minutes Walking Test in Hip Fracture Patients

The purpose of this study is to examine the relative (ICC) and absolute intertester reliability of the 6-Minutes Walking Test in hip fracture patients (N=50) in an outpatient facility. The data collection is conducted by two physiotherapists, who are blinded to each other. The physiotherapists are randomized so they each are doing an equal number of baseline tests.


Eligibility Criteria:
Inclusion Criteria:

* 60 years or above
* Hip fracture patients with a Intra - or Extra Capsular hip fracture
* Testing within 3 - 5 weeks postsurgery in an outpatient facility
* No weightbearing restrictions on the fractured limb
* Normal cognitive level (Mini Mental State Examination(MMSE) - score ≥20 points)
* Participants should not experiencing hip related pain more or less than moderate according to Verbal Ranking Scale when resting
* To have the ability to write and understand danish language

Exclusion Criteria:

- MMSE score ≤19 points
Mental Health and Academic Performance in COVID-19

This study aims to identify the preference of the class modalities (classroom or online) in undergraduate and graduate students. Additionally, to explore if the presence of any mental state alterations such as depression or anxiety due to the COVID-19 pandemic can alter their perception of academic performance.


Eligibility Criteria:
Inclusion Criteria:

* \> 18 years
* Students of any undergraduate or graduate course who are attending their semester online

Exclusion Criteria:

* Students who are not attending an online course
* Students who are not registered in a university undergraduate or graduate course.
Peers EXCEL Trial to Improve Glycemic Control

The purpose of the study is to gather input about the value of adding a newly developed diabetes self-management program to an existing diabetes self-management program. Participants will self-identify as African-American/Black with type 2 diabetes, and prescribed a diabetes medication. Participants can expect to be in the study for 6 months.

Both programs utilized in this study focus on topics such as diet, exercise, and stress. Both programs offer ideas to manage diabetes symptoms, discuss appropriate exercises, provide guidance on healthy eating, review the use of medicine, and offer tips on communicating with healthcare providers and voicing concerns to family members.

The new program is culturally-tailored for African Americans and focuses on helping patients take their medicines as prescribed.

The purpose of this research study is to evaluate this newly developed combined diabetes self-management program.

Eligibility Criteria:
Inclusion Criteria:

* Between 18-90 years old
* Self-identify as African-American
* Diagnosis of Type 2 diabetes
* Able to speak/read English
* Self-report having a primary care provider who prescribes one diabetes medication
* Diagnosed with diabetes for ≥1 year at point of care
* Will reside in the geographical area throughout the study period
* Self-reported nonadherence on the DOSE-nonadherence survey
* ≥7.5% A1C

Exclusion Criteria:

* Self-reported bipolar or personality disorders, schizophrenia, Alcohol and Other Drug Abuse (AODA), dementia
* Older adults who have a history of severe hypoglycemia requiring medical assistance or glucagon administration
* Participating in another lifestyle or medication adherence program
Prehospital Cerebral Oxygenation During Cardiopulmonary Resuscitation (CPR)

Near infrared spectroscopy (NIRS) is a technique that measures regional cerebral oxygenation in a non-invasive manner. Through the use of near infrared light, the difference between oxygenated and deoxygenated hemoglobin can be measured. By applying the Beer-Lamber law, a numeric result can be calculated. During a cardiac arrest, there is no stroke volume, no cardiac output and no cerebral perfusion. By using cerebral NIRS during out-of hospital cardiac arrest, low flow time and return of spontaneous circulation, this study wants to show the prognostic value of NIRS as extra monitoring.


Eligibility Criteria:
Inclusion Criteria:

* \>16 year

Exclusion Criteria:

* DNR code